New guidelines for the heart failure treatment (2021) Review article
Article Sidebar
Published:
Dec 31, 2021
Keywords:
guidelines, heart failure, converting enzyme inhibitors, sacubitril, valsartan, β-blockers, mineralocorticoid receptor inhibitors, sodium-glucose co-transporter inhibitors
Main Article Content
Abstract
At this year’s ESC congress in London, it was announced an update of the guidelines for the treatment of chronic heart failure with reduced left ventricular ejection fraction. Key change compared to last guidelines is withdrawal the long-term titration strategy and introducing a simpler and faster regimen based on four groups of drugs: blocking the renin–angiotensin–aldosterone system (ACE-I, ARNI), sodium-glucose co-transporter inhibitors (dapagliflozin, empagliflozin), β-adrenolytic drugs, mineralocorticoid receptor inhibitors.
Article Details
How to Cite
Grabysa , R. (2021). New guidelines for the heart failure treatment (2021). Medycyna Faktow (J EBM), 14(4(53), 338-342. https://doi.org/10.24292/01.MF.0421.1
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. McDonagh TA, Metra M, Adamo M et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; 42(36): 3599-726. http://doi.org/10.1093/eurheartj/ehab368.
2. Brunner-La Rocca HP, Linssen GC et al. Contemporary Drug Treatment of Chronic Heart Failure With Reduced Ejection Fraction: The CHECK-HF Registry. JACC Heart Fail. 2019; 7(1): 13-21. http://doi.org/10.1016/j.jchf.2018.10.010.
3. Thomas MC. Renal effects of dapagliflozin in patients with type 2 diabetes. Ther Adv Endocrinol Metab. 2014; 5(3): 53-61. http://doi.org/10.1177/2042018814544153.
4.Verma S, McMurray JJV, Cherney DZI. The Metabolodiuretic Promise of Sodium-Dependent Glucose Cotransporter 2 Inhibition: The Search for the Sweet Spot in Heart Failure. JAMA Cardiol. 2017; 2(9): 939-40. http://doi.org/10.1001/jamacardio.2017.1891.
5. Zinman B, Wanner C, Lachin JM et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015; 373(22): 2117-28. http://doi.org/10.1056/NEJMoa1504720.
6. Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016; 37(27): 2129-200. http://doi.org/10.1093/eurheartj/ehw128.
7. McMurray JJV, Solomon SD, Inzucchi SE et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019; 381(21): 1995-2008. http://doi.org/10.1056/NEJMoa1911303.
8. Packer M, Anker SD, Butler J et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020; 383(15): 1413-24. http://doi.org/10.1056/NEJMoa2022190.
9. DeVore AD, Braunwald E, Morrow DA et al. Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial. JAMA Cardiol. 2020; 5(2): 202-7. http://doi.org/10.1001/jamacardio.2019.4665.
10.Vaduganathan M, Claggett BL, Jhund PS et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet. 2020; 396(10244): 121-8. http://doi.org/10.1016/S0140-6736(20)30748-0.
11. Straw S, McGinlay M, Witte KK. Four pillars of heart failure: contemporary pharmacological therapy for heart failure with reduced ejection fraction. Open Heart. 2021; 8(1): e001585. http://doi.org/10.1136/openhrt-2021-001585.
2. Brunner-La Rocca HP, Linssen GC et al. Contemporary Drug Treatment of Chronic Heart Failure With Reduced Ejection Fraction: The CHECK-HF Registry. JACC Heart Fail. 2019; 7(1): 13-21. http://doi.org/10.1016/j.jchf.2018.10.010.
3. Thomas MC. Renal effects of dapagliflozin in patients with type 2 diabetes. Ther Adv Endocrinol Metab. 2014; 5(3): 53-61. http://doi.org/10.1177/2042018814544153.
4.Verma S, McMurray JJV, Cherney DZI. The Metabolodiuretic Promise of Sodium-Dependent Glucose Cotransporter 2 Inhibition: The Search for the Sweet Spot in Heart Failure. JAMA Cardiol. 2017; 2(9): 939-40. http://doi.org/10.1001/jamacardio.2017.1891.
5. Zinman B, Wanner C, Lachin JM et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015; 373(22): 2117-28. http://doi.org/10.1056/NEJMoa1504720.
6. Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016; 37(27): 2129-200. http://doi.org/10.1093/eurheartj/ehw128.
7. McMurray JJV, Solomon SD, Inzucchi SE et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019; 381(21): 1995-2008. http://doi.org/10.1056/NEJMoa1911303.
8. Packer M, Anker SD, Butler J et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020; 383(15): 1413-24. http://doi.org/10.1056/NEJMoa2022190.
9. DeVore AD, Braunwald E, Morrow DA et al. Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial. JAMA Cardiol. 2020; 5(2): 202-7. http://doi.org/10.1001/jamacardio.2019.4665.
10.Vaduganathan M, Claggett BL, Jhund PS et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet. 2020; 396(10244): 121-8. http://doi.org/10.1016/S0140-6736(20)30748-0.
11. Straw S, McGinlay M, Witte KK. Four pillars of heart failure: contemporary pharmacological therapy for heart failure with reduced ejection fraction. Open Heart. 2021; 8(1): e001585. http://doi.org/10.1136/openhrt-2021-001585.